Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218822

SCHEMBL23218822

SCHEMBL23218822

CCOC(=O)Cc1ccccc1OCc1coc2c(CBr)cc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBXAS1 P24557 1/20 0.40
▸ CFD P00746 2/20 0.37
▸ MAPT P10636 4/20 0.37
▸ TP53 P04637 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ PKM P14618 1/20 0.36
▸ SLC1A5 Q15758 1/20 0.35
▸ PTGER1 P34995 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ DUSP3 P51452 1/20 0.35
▸ PTPN5 P54829 1/20 0.35
▸ PTPN11 Q06124 1/20 0.35
▸ CTDSP1 Q9GZU7 1/20 0.35
▸ F11 P03951 1/20 0.34
▸ TPSB2 P20231 1/20 0.34
▸ MEN1 O00255 4/20 0.34
▸ KMT2A Q03164 4/20 0.34
▸ POLB P06746 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853078 1.00 TBXAS1 (0.40) TBXAS1CFDMAPTTP53THRB
SCHEMBL28736329 0.92 TBXAS1 (0.39) TBXAS1CFDMAPTTP53THRB
SCHEMBL29592551 0.91 TBXAS1 (0.41) TBXAS1CFDMAPTTP53THRB
SCHEMBL23229205 0.91 TBXAS1 (0.41) TBXAS1CFDMAPTTP53THRB
SCHEMBL23218255 0.91 TBXAS1 (0.41) TBXAS1CFDMAPTTP53THRB
SCHEMBL29852978 0.91 TBXAS1 (0.41) TBXAS1CFDMAPTTP53THRB
SCHEMBL23219051 0.90 TBXAS1 (0.39) TBXAS1CFDMAPTTP53THRB
SCHEMBL29852526 0.90 TBXAS1 (0.39) TBXAS1CFDMAPTTP53THRB
SCHEMBL23218048 0.89 TBXAS1 (0.39) TBXAS1CFDMAPTTP53THRB
SCHEMBL29853013 0.89 TBXAS1 (0.39) TBXAS1CFDMAPTTP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TBXAS1 963/4885CFD 1/4885MAPT 4793/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 392/4885CFD 1/4885MAPT 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.